Q&A with Deborah Tanner, Covance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Deborah Tanner, Covance
A Q&A with Deborah Tanner, executive vice-president and group president of R&D laboratories at Covance, on recent industry trends.

Pharmaceutical Technology
pp. 56

Deborah Tanner, executive vice-president and group president of R&D laboratories at Covance


Deborah Tanner
PharmTech:
How will the industry remain innovative as it reduces spending on research?

Tanner:
Drug-development outsourcing appears to be one of the best models to reduce pharmaceutical clients' fixed costs and drive industry innovation. For pharmaceutical companies, it's often a matter of determining what's core and what's not core to their business. As a strategic partner to such clients as Lilly, Sanofi, Otsuka, and Merck, we work in joint functional teams to plan resources, share data, identify opportunities, and resolve issues for better outcomes.

Another force behind innovation and cost savings are asset transfers, which have been a component of some of our strategic partnerships. Since acquiring the former Lilly site in Greenfield, Indiana, in 2008, we've expanded the site to include biorepository and developmental and reproductive toxicology services. What used to be an in-house resource serving one company is now a hub serving more than 50 clients and driving drug development across multiple therapeutic areas.

PharmTech:
Do you see a new industry trend emerging?

Tanner:
Strategic outsourcing has created the most exciting and dynamic shift in the history of the contract research industry. It's been a game-changer for pharmaceutical and biotech R&D because it serves the industry's two most pressing, and perhaps conflicting, needs: to reduce costs and to get safe and effective new medicines to patients faster.

We also see some trends in certain service lines. Take chemistry, manufacturing, and controls services. In formulation, we're seeing more and more APIs with solubility issues. Designing the most appropriate physicochemical properties and the best formulation strategy to increase solubility, bioavailability, and permeability is more important than ever. Covance has a dedicated team of experts focused on API characterization, preformulation, and formulation development to help clients optimize their compounds.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here